DOCSLIB.ORG

Method Development and Validation of Trazodone Hydrochloride (Hcl)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Method Development and Validation of Trazodone Hydrochloride (Hcl) The International journal of analytical and experimental modal analysis ISSN NO:0886-9367 METHOD DEVELOPMENT AND VALIDATION OF TRAZODONE HYDROCHLORIDE (HCL) Madhu s. shewale*, Suhas siddheshwar, Mahesh kolhe Department of pharmaceutical quality assurance technique, Pravara rural college of pharmacy , pravaranagar ,Tal-rahata, Dist-ahamadnagar, 413736. Abstract : The objective of the present investigation was method development and validation of trazadone hydrochloride using u.v detection was developed and validated using C-18,250 x 4.6mm, 5u column and mobile phase composition was buffer(pot.Dihydrogen ortho phosphate):acetonitrile 65:35 at the flow rate of 1.0 ml/min. monitoring wavelength used was 248 nm, with u.v detection run time was selected to be 7 min because the peaks for trazodone hydrochloride were observed around 3.02 min. the method was validated as per ICH guideline for various parameters like accuracy ,linearity precision , robustness ,ruggedness, LOD, LOQ studies the precision of the system and method were checked and was found to be within the limits these indicates the method is precise correlation coefficient was found to be 0.999. the recovery value of pure drug found between 80.0% to 120.0% which indicates that method is accurate and also reveales that commonly used excipients and additives present in the pharmaceutical formulation were not interfering in the proposed analytical method passed both robustness and ruggedness test .on both cases ,relative standard deviation was well satisfactory . the proposed method can be used for routine analysis of trazodone hydrochloride commercial tablet dosage form in very less time. KEYWORD : Trazodone Hydrochloride , method development, validation . Volume XII, Issue IX, September/2020 Page No:1705 The International journal of analytical and experimental modal analysis ISSN NO:0886-9367 INTRODUCTION : Method Development And Validation Aspect By Assay Method ​ ​ Accurately reflect the purity characteristic of sample , assay procedure are intended to measure the analyte present . By using Analytical methods development and validation assume imperative parts in the discovery, improvement and preparation of pharmaceuticals. Method development is the way toward demonstrating that a analytical strategy is satisfactory for use to measure the concentration of an active pharmaceutical ingredient (API) in a particular formulated dosage form which enables simplified methods to be utilized to check that an analytical procedure, precisely and reliably will convey a reliable estimation of an active ingredient in an compounded preparation. The analytical strategy validation is important for analytical technique improvement and tested widely for specificity, linearity, exactness, accuracy, precision, range, detection limit, quantization limit, and robustness. In outline, analytical method development and validation permits to affirm that an exact and reliable potency estimation of a pharmaceutical preparation can be performed. Importance of pharmaceutical analysis This analysis will disclose the categorization, recognition, and purpose of the raw materials, final products, and biological products. The numbers of different types of drugs are increasing rapidly at an alarming rate in the current condition. All these new entrances are either the new entities or the incomplete structural amendments of the exciting ones. To guarantee the safety of new drugs, it is imperative to use an appropriate pharmaceutical analysis. At the present new analytical methods are approaching up for these new drugs and those amalgamations due to several motives. A few of them are subsequent. High Performance Liquid Chromatography / High Pressure Liquid Chromatography Is a form of liquid chromatography used to separate compound that are dissolved in solution Hplc instruments consist of : 1.Reservoir of mobile phase 2.A pump 3.An injector 4.Separation column Volume XII, Issue IX, September/2020 Page No:1706 The International journal of analytical and experimental modal analysis ISSN NO:0886-9367 5.Detector ❖ Reservoir of mobile phase – reservoir can be any clean ,inert container it usually contains 0.5-2L of solvent and it should have a cap that allows for a tubing inlet line which feeds mobile phase to solvent delivery system. ❖ Pumps-pushes mobile phase from reservoir and pulls to detector it helps to maintain flow rate Columns- are usually long narrow tubes containing stationary phase. ❖ Injection system is way of introducing sample into mobile phase . Detector in HPLC is used to monitor mobile phase that emerges from column . MATERIALS AND METHODS: APPARATUS: Analysis of the drug was carried out on a 1. HPLC –thermo scientific (all parts) equipped with pump and U.V detector was used and coloumn 250x 4,6mm,C18 , 2. UV Labindia Model no.-T60, 3. IR jasco, Model no. –FTIR 4100, Oven- Oswald, balance make essae ,PH meter –Labindia Balance capacity Min 0.0001g Max220 g. CHEMICAL AND MATERIAL : Trazodone hydrochloride sample was obtained from piramal healthcare ltd . solvent used are acetotnitrile HPLC grade which were from qualigen pharma pvt.ltd, buffer (potassium dihydrogen orthophosphate ) AR grade from merck LTD . sonicator for remo val of small suspended gas bubbles ,for purpose of weighing analytical weighing balance (make : ESSAE,VIBRA+,CAPA: 220g to 0.0001 g ) was used CHROMATOGRAPHIC CONDITION : Quantification of trazodone hydrochloride was carried out on cromasil C18 column with dimension 250x4.6mm, the mobile phase used was in ratio 65%buffer(potassium dihydrogen ortho phosphate and acetonitrile 35% ,the flow rate of solvent optimised for the analysis was 1.0ml/min and was detected at 248nm wavelength, the injection volume of sample in HPLC system was 10ul . Volume XII, Issue IX, September/2020 Page No:1707 The International journal of analytical and experimental modal analysis ISSN NO:0886-9367 PREPARATIONS : Preparation of Mobile Phase: Take 0.1 M Potassium Dihydrogen orthophosphate and Acetonitrile in a ratio of (65:35%) v/v. Preparation of buffer : 0.1 pot. Dihydrogen orthophosphate in 1 lit mix and filter through 0.45um filter paper. Preparation of Stock Solution : Take 5mg of TRAZADON HCL and dilute it upto 50ml of mobile phase which will make a stock solution of 100ppm Standard solution : Take 10ml from above stock solution and dilute it up to 100ml of mobile phase which will makes a solution of 10ppm. The primary objective of validation is to form a basis for the written procedure for production and process control which are designed to assure that the drug products have the identity, quality, and purity they purport are represented to possess. Assurance of Quantity Government Regulation 1.4.2 Validation parameters Typical analytical parameters used in validation include: ❖ Specificity ❖ Precision ❖ Accuracy ❖ Linearity ❖ Range ❖ Robustness ❖ Limit of detection ❖ Limit of quantification Volume XII, Issue IX, September/2020 Page No:1708 The International journal of analytical and experimental modal analysis ISSN NO:0886-9367 ❖ 1.4.2.1 Specificity ❖ It is an ability to assess unequivocally the analyte in the presence of components which may be expected to be present. Typically these might include impurities, degradants, matrix, etc. ❖ 1.4.2.2 Precision ❖ A Precision may be considered at three levels: repeatability, intermediate precision, and reproducibility. ❖ Precision should be investigated using homogeneous, authentic samples. However, if it is not possible to obtain a homogeneous sample it may be investigated using artificially prepared samples or a sample solution. ❖ The precision of an analytical procedure is usually expressed as the variance, standard deviation, or coefficient of variation of a series of measurements. ❖ Repeatability ❖ Repeatability expresses the precision under the same operating conditions over a short interval of time. Repeatability is also termed intra-assay precision. ❖ Intermediate precision ❖ Intermediate precision expresses within-laboratories variations: different days, different analysts, different equipment, etc. ❖ Reproducibility ❖ Reproducibility expresses the precision between laboratories (collaborative studies, usually applied to the standardization of methodology). ❖ 1.4.2.3 Accuracy ❖ The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found. This is sometimes termed trueness. Volume XII, Issue IX, September/2020 Page No:1709 The International journal of analytical and experimental modal analysis ISSN NO:0886-9367 ❖ 1.4.2.4 Detection limit ❖ The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value. ❖ Several approaches for determining the detection limit are possible, depending on whether the procedure is a non-instrumental or instrumental. Approaches other than those listed below may be acceptable. ❖ Based on Visual Evaluation ❖ A visual evaluation may be used for non-instrumental methods but may also be used with instrumental methods. ❖ The detection limit is determined by the analysis of samples with known concentrations of analyte and by establishing the minimum level at which the analyte can be reliably detected. ❖ Based on Signal-to-Noise ❖ This approach can only be applied to analytical procedures that exhibit baseline noise. ❖ Determination of the signal-to-noise ratio is performed
Load more

Recommended publications
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Original Article E€Ects of Serotonin 1A Agonist on Acute Spinal Cord Injury
    Spinal Cord (2002) 40, 519 ± 523 ã 2002 International Spinal Cord Society All rights reserved 1362 ± 4393/02 $25.00 www.nature.com/sc Original Article Eects of serotonin 1A agonist on acute spinal cord injury Y Saruhashi*,1, Y Matsusue1 and S Hukuda2 1Department of Orthopedic Surgery, Shiga University of Medical Science, Otsu, Japan; 2Tane-daini Hospital, Osaka, Japan Study design: We evaluated the eects of serotonin (5-HT) agonists on in vitro models of spinal cord compressive injury. Evoked potentials in injured rat spinal cords (n=24) were recorded during perfusion with 5-HT agonists. Objectives: To evaluate the therapeutic eects of 5-HT agonists on the recovery of compound action potentials in injured spinal cords. Methods: Rat dorsal columns were isolated, placed in a chamber, and injured by extradural compression with a clip. Conducting action potentials were activated by supramaximal constant current electrical stimuli and recorded during perfusion with 5-HT agonists and antagonists. Results: After inducing compression injuries, mean action potential amplitudes were reduced to 33.9+5.4% of the pre-injury level. After 120 min of perfusion with Ringer's solution, the mean amplitudes recovered to 62.8+8.4% of the pre-injury level. At a concentration of 100 mM, perfusion with tandospirone (a 5-HT1A agonist) resulted in a signi®cantly greater recovery of mean action potential amplitudes at 2 h after the injury (86.2+6.9% of pre-injury value) as compared with the control Ringer's solution (62.8+8.4% of pre-injury value, P50.05). In contrast, quipazine (a 5-HT2A agonist) accelerated the decrease of amplitude (54.5+11.7% of pre-injury value).
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • 5-HT1A Receptor-Dependent Modulation of Emotional
    www.nature.com/scientificreports OPEN 5-HT1A receptor-dependent modulation of emotional and neurogenic defcits elicited by Received: 8 May 2017 Accepted: 19 January 2018 prolonged consumption of alcohol Published: xx xx xxxx Arnauld Belmer 1,2, Omkar L. Patkar1,2, Vanessa Lanoue3 & Selena E. Bartlett 1,2 Repeated episodes of binge-like alcohol consumption produce anxiety, depression and various deleterious efects including alterations in neurogenesis. While the involvement of the serotonin receptor 1 A (5-HT1A) in the regulation of anxiety-like behavior and neurogenesis is well documented, its contribution to alcohol withdrawal-induced anxiety and alcohol-induced defcits in neurogenesis is less documented. Using the Drinking-In-the-Dark (DID) paradigm to model chronic long-term (12 weeks) binge-like voluntary alcohol consumption in mice, we show that the selective partial activation of 5-HT1A receptors by tandospirone (3 mg/kg) prevents alcohol withdrawal-induced anxiety in a battery of behavioral tests (marble burying, elevated-plus-maze, open-feld), which is accompanied by a robust decrease in binge-like ethanol intake (1 and 3 mg/kg). Furthermore, using triple immunolabelling of proliferation and neuronal diferentiation markers, we show that long-term DID elicits profound defcits in neurogenesis and neuronal fate specifcation in the dorsal hippocampus that are entirely reversed by a 2-week chronic treatment with the 5-HT1A partial agonist tandospirone (3 mg/kg/day). Together, our results confrm previous observations that 5-HT1A receptors play a pivotal role in alcohol drinking behavior and the associated emotional and neurogenic impairments, and suggest that 5-HT1A partial agonists represent a promising treatment strategy for alcohol abuse.
    [Show full text]
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review
    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
    [Show full text]
  • A Systematic Review of the Effectiveness of Antianxiety and Antidepressive Agents for Functional Dyspepsia
    doi: 10.2169/internalmedicine.9099-17 Intern Med 56: 3127-3133, 2017 http://internmed.jp 【 ORIGINAL ARTICLE 】 A Systematic Review of the Effectiveness of Antianxiety and Antidepressive Agents for Functional Dyspepsia Mariko Hojo 1, Akihito Nagahara 2, Daisuke Asaoka 1, Yuji Shimada 2, Hitoshi Sasaki 3, Kohei Matsumoto 1, Tsutomu Takeda 1, Hiroya Ueyama 1, Kenshi Matsumoto 1 and Sumio Watanabe 1 Abstract: Objective Functional dyspepsia (FD) is defined as persistent or recurrent pain or discomfort centered in the upper abdomen without organic disease. Psychosocial factors have been proposed as an important element in the pathophysiology of FD. Therefore, psychotropic agents having antianxiety or antidepressive action are ex- pected to alleviate FD. We previously reported on the treatment of FD using such agents in a systematic re- view, wherein the effectiveness of the agents on FD was suggested, although there were several limitations. We searched for articles on this subject after our systematic review and re-reviewed them systematically. Methods Articles were searched for in MEDLINE from 2003 to 2014 using terms related to antianxiety or antidepressive agents. Clinical studies in which the effectiveness of such agents was clearly stated were se- lected from the retrieved articles. The newly selected and previously selected studies were combined, and sta- tistical analyses were carried out. Results Nine studies were selected. Five of the studies indicated a significant symptomatic improvement us- ing psychotropic drugs. A statistical analysis suggested a significant treatment effect of psychotropic agents having antianxiety or antidepressive action [pooled relative risk (PRR), 0.72; 95% confidence interval (95% CI), 0.52-0.99; p=0.0406] but did not show a significant benefit of treatment with agents having an antide- pressive action alone (PRR, 0.63; 95% CI, 0.38-1.03; p=0.0665).
    [Show full text]
  • Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders
    Neuropsychopharmacology (2003) 28, 402–412 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders ,1 2 3 2 Gerard J Marek* , Linda L Carpenter , Christopher J McDougle and Lawrence H Price 1Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 2Department of Psychiatry and Human, Brown Medical School, Mood 3 Disorders Program, Behavior, Butler Hospital, Providence, RI, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA Recently, the addition of drugs with prominent 5-HT2 receptor antagonist properties (risperidone, olanzapine, mirtazapine, and mianserin) to selective serotonin reuptake inhibitors (SSRIs) has been shown to enhance therapeutic responses in patients with major depression and treatment-refractory obsessive–compulsive disorder (OCD). These 5-HT antagonists may also be effective in 2 ameliorating some symptoms associated with autism and other pervasive developmental disorders (PDDs). At the doses used, these drugs would be expected to saturate 5-HT2A receptors. These findings suggest that the simultaneous blockade of 5-HT2A receptors and activation of an unknown constellation of other 5-HT receptors indirectly as a result of 5-HT uptake inhibition might have greater therapeutic efficacy than either action alone. Animal studies have suggested that activation of 5-HT1A and 5-HT2C receptors may counteract the effects of activating 5-HT2A receptors. Additional 5-HT receptors, such as the 5-HT1B/1D/5/7 receptors, may similarly counteract the effects of 5-HT receptor activation. These clinical and preclinical observations suggest that the combination of highly 2A selective 5-HT antagonists and SSRIs, as well as strategies to combine high-potency 5-HT receptor and 5-HT transporter blockade in 2A 2A a single compound, offer the potential for therapeutic advances in a number of neuropsychiatric disorders.
    [Show full text]
  • Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gutlbrain Interaction): a Rome Foundation Working Team Report Douglas A
    Gastroenterology 2018;154:1140–1171 SPECIAL REPORT Neuromodulators for Functional Gastrointestinal Disorders (Disorders of GutLBrain Interaction): A Rome Foundation Working Team Report Douglas A. Drossman,1,2 Jan Tack,3 Alexander C. Ford,4,5 Eva Szigethy,6 Hans Törnblom,7 and Lukas Van Oudenhove8 1Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, North Carolina; 2Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology, Chapel Hill, North Carolina; 3Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; 4Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom; 5Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, United Kingdom; 6Departments of Psychiatry and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 7Departments of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and 8Laboratory for BrainÀGut Axis Studies, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium BACKGROUND & AIMS: Central neuromodulators (antide- summary information and guidelines for the use of central pressants, antipsychotics, and other central nervous neuromodulators in the treatment of chronic gastrointestinal systemÀtargeted medications) are increasingly used for treat- symptoms and FGIDs. Further studies are needed to confirm ment
    [Show full text]
  • Trazodone-Induced Mania in a Unipolar Depressed Patient with Stable Sertraline Treatment
    Journal name: Neuropsychiatric Disease and Treatment Article Designation: Case report Year: 2017 Volume: 13 Neuropsychiatric Disease and Treatment Dovepress Running head verso: Hu et al Running head recto: Trazodone-induced mania in a unipolar depressed patient open access to scientific and medical research DOI: http://dx.doi.org/10.2147/NDT.S143965 Open Access Full Text Article CASE REPORT Fan the flame: trazodone-induced mania in a unipolar depressed patient with stable sertraline treatment Jianbo Hu1,2,* Abstract: Depressed patients often complain of sleep disturbance. Routine antidepressive Jianbo Lai1,2,* strategies sometimes fail to deal with this intractable issue. Indeed, the supplementation of Hanzhi Zheng3 sleep promoting antidepressants (eg, trazodone, mirtazapine, and agomelatine) is prevalent Shaohua Hu1,2 in clinical practice. However, the combination of different antidepressants may increase the Yi Xu1,2 affective lability. Herein, we document a patient with unipolar depression who was compliant with sertraline treatment and who dramatically switched to mania after adding trazodone as a 1Department of Psychiatry, First sleeping aid. This case extended our understanding of the potential manic-switching risk when Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, trazodone is used to promote sleep. 2 China; The Key Laboratory of Keywords: trazodone, sertraline, depression, mania Mental Disorder’s Management in For personal use only. Zhejiang Province, Hangzhou, China; 3Department of Clinical Medicine,
    [Show full text]
  • Proneurogenic Effects of Trazodone in Murine and Human Neural
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Research Article pubs.acs.org/chemneuro Proneurogenic Effects of Trazodone in Murine and Human Neural Progenitor Cells † § ∥ ∥ † § † § Valeria Bortolotto, , Francesca Mancini, Giorgina Mangano, Rita Salem, , Er Xia, , ‡ § ‡ § § ∥ Erika Del Grosso, , Michele Bianchi, , Pier Luigi Canonico, Lorenzo Polenzani, † § and Mariagrazia Grilli*, , † ‡ § Laboratory of Neuroplasticity, Laboratory of Pharmaceutical Analysis, and Department of Pharmaceutical Sciences, University of Piemonte Orientale “Amedeo Avogadro”, Via Bovio 6, Novara 28100, Italy ∥ Angelini S.p.A, RR&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba-Pomezia, Roma, Italy ABSTRACT: Several antidepressants increase adult hippocampal neurogenesis (ahNG) in rodents, primates, and, potentially, humans. This effect may at least partially account for their therapeutic activity. The availability of antidepressants whose mechanism of action involves different neurotransmitter receptors represents an opportunity for increasing our knowledge on their distinctive peculiarities and for dissecting the contribution of receptor subtypes in ahNG modulation. The aim of this study was to evaluate, in vitro, the effects of the antidepressant trazodone (TZD) on ahNG by using primary cultures of murine adult hippocampal neural progenitor cells (ahNPCs) and human induced pluripotent stem cell (iPSC)-derived NPCs. We demonstrated that TZD enhances neuronal differentiation of murine as well as human NPCs. TZD is a multimodal antidepressant, which binds with high ffi α ffi a nity to 5-HT2a, 1, and 5-HT1a and with lower a nity to 5-HT2c, α ff 2 and 5-HTT. We demonstrated that TZD proneurogenic e ects were mediated by 5-HT2a antagonism both in murine and in κ human NPCs and by 5-HT2c antagonism in murine cells.
    [Show full text]
  • The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects
    The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects Guido K. W. Frank & Megan E. Shott CNS Drugs ISSN 1172-7047 CNS Drugs DOI 10.1007/s40263-016-0335-6 1 23 Your article is protected by copyright and all rights are held exclusively by Springer International Publishing Switzerland. This e- offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy CNS Drugs DOI 10.1007/s40263-016-0335-6 REVIEW ARTICLE The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects 1,2 1 Guido K. W. Frank • Megan E. Shott Ó Springer International Publishing Switzerland 2016 Abstract Anorexia nervosa (AN) is a severe psychiatric disorder without approved medication intervention. Every Key Points class of psychoactive medication has been tried to improve treatment outcome; however, randomized controlled trials Anorexia nervosa (AN) is a severe psychiatric illness have been ambiguous at best and across studies have not with a complex interplay of bio-psycho-social shown robust improvements in weight gain and recovery.
    [Show full text]
  • Multi-Target Approach for Drug Discovery Against Schizophrenia
    Review Multi-Target Approach for Drug Discovery against Schizophrenia Magda Kondej 1, Piotr Stępnicki 1 and Agnieszka A. Kaczor 1,2,* 1 Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, 4A Chodźki St., Lublin PL-20093, Poland; [email protected] (M.K.); [email protected] (P.S.) 2 School of Pharmacy, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, Kuopio FI-70211, Finland * Correspondence: [email protected]; Tel.: +48-81-448-7273 Received: 3 September 2018; Accepted: 6 October 2018; Published: 10 October 2018 Abstract: Polypharmacology is nowadays considered an increasingly crucial aspect in discovering new drugs as a number of original single-target drugs have been performing far behind expectations during the last ten years. In this scenario, multi-target drugs are a promising approach against polygenic diseases with complex pathomechanisms such as schizophrenia. Indeed, second generation or atypical antipsychotics target a number of aminergic G protein-coupled receptors (GPCRs) simultaneously. Novel strategies in drug design and discovery against schizophrenia focus on targets beyond the dopaminergic hypothesis of the disease and even beyond the monoamine GPCRs. In particular these approaches concern proteins involved in glutamatergic and cholinergic neurotransmission, challenging the concept of antipsychotic activity without dopamine D2 receptor involvement. Potentially interesting compounds include ligands interacting with glycine modulatory binding pocket on N-methyl-D-aspartate (NMDA) receptors, positive allosteric modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, positive allosteric modulators of metabotropic glutamatergic receptors, agonists and positive allosteric modulators of α7 nicotinic receptors, as well as muscarinic receptor agonists.
    [Show full text]